PTO/SB/08a (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2

Complete if Known	
Application Number	**10/585,928**
Filing Date	**July 13, 2006**
First Named Inventor	**ZIV, Ilan**
Art Unit	**1615**
Examiner Name	**SAMALA, JAGADISHWAR RAO**
Attorney Docket Number	**P-8972-US**

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A	US-4 187 381	Feb. 5, 1980	G. W. Holland	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B	WO 97/00848	Jan. 9, 1997	BNFL Fluorochemichals		☐
	C	JP 57 085338	May 28, 1982	DAIKIN		☐
	D	FR 2 274 600	Jan. 9, 1976	SANDOZ		☐
	E	FR 2 197 873	Mar. 29, 1974	RICHTER, Gedeon		☐
						☐
						☐
						☐
						☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-05)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/585,928
				Filing Date	July 13, 2006
				First Named Inventor	ZIV, Ilan
				Art Unit	1615
(use as many sheets as necessary)				Examiner Name	SAMALA, JAGADISHWAR RAO
Sheet	2	of	2	Attorney Docket Number	P-8972-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	F	GERSHON H. Organic fluorine compounds.II., Journal of Medicinal Chemistry, 1967, p. 186-188, vol. 10, no. 2, American Chemical Society	☐
	G	BEVERS, E.M., et al., Lipid translocation across the plasma membrane of mammalian cells, Biochimica et Biophysica Acta 1439 (1999) 317-330 Elsevier	☐
	H	BOMBELI, T., et al, Apoptotic Vascular Endothelial Cells Become Procoagulant, Blood, April 1, 1997, pp 2429-2442, Vol 89, No 7. American Society of Hematology, Washington DC	☐
	I	BRATTON, D.L., et al, Appearance of Phosphatidylserine on Apoptotic Cells Requires Calcium-mediated Nonspecific Flip-Flop and Is Enhanced by Loss of the Aminophospholipid Translocase, The Journal Of Biological Chemistry, October 17, 1997, pp. 26159–26165, Vol. 272, No. 42, The American Society for Biochemistry and Molecular Biology, Inc.	☐
	J	BURSCH, W., et al, Cell death by apoptosis and its protective role against disease, Trends Pharmacol Sci. 1992 Jun;13(6):245-51.	☐
	K	KOCKX M.M., et al, Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res., 2000, 736–746, vo. 45, Elsevier	☐
	L	MALLAT, Z., et al, Colocalization of CPP-32 With Apoptotic Cells in Human Atherosclerotic Plaques Circulation, 1997; 424-428 Vol. 96, American Heart Association, Inc.	☐
	M	MARTIN, S., et al, Early Redistribution of Plasma Membrane Phosphatidylserine Is a General Feature of Apoptosis Regardless of the Initiating Stimulus: Inhibition by Overexpression of Bcl-2 and Abl, J. Exp.Med, November 1, 1995, 1545 Vol. 182	☐
	N	PUGSLEY, W., et al, The impact of microemboli during cardiopulmonary bypass on neuropsychological functioning, Stroke, 1994, 1393-1399, Vol 25, American Heart Association	☐
	O	SIMS, P.J., et al, Unraveling the Mysteries of Phospholipid Scrambling Thromb. Haemost, 2001; p. 266–75, Vol. 86, Schattauer GmbH, Stuttgart	
	P	STARY, H.C., et al., A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis, Circulation, 1995, p. 1355-1374, Vol. 92, American Heart Association, Inc.	☐
	Q	VAN DEN EIJNDE, S.M., et al, Phosphatidylserine plasma membrane asymmetry in vivo: a pancellular phenomenon which alters during apoptosis, Cell Death Differentiation, 1997, p. 311-316, Vol. 4, Stockton Press	☐

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.